The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The unmet needs in AL amyloidosis and limitations of the current SoC
Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, provides insights into the unmet needs for patients with light chain (AL) amyloidosis, and highlights the need for an approved standard of care (SoC) for patients with advanced disease. Patients with Mayo cardiac stage IIIa disease or higher have been excluded from previous clinical trials, meaning that data to inform optimal SoC in this patient group is insufficient. Dr Milani eagerly anticipates the prospective data from several ongoing clinical trials which focus on treating advanced AL amyloidosis in a controlled setting, and hopes that with more knowledge in this space, the number of patients reaching advanced disease will decrease. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Pfizer, Jannsen-Cilag
Membership on Board of Directors or advisory committee: Jannsen-Cilag, Siemens
